Prevalence of CYP2C9 and VKORC1 alleles in the argentine population and implications for prescribing dosages of anticoagulants

Genetics and Molecular Research

Volumn 11, Issue 1, 2012, Pages 70-76

  Scibona, P ^a   Redal, M A ^a   Garfi, L G ^a   Arbelbide, J ^a   Argibay, P F ^a   Belloso, W H ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Allelic frequency; Anticoagulant; Argentina; CYP2C9; Pharmacogenomics; VKORC1

Indexed keywords

COUMARIN ANTICOAGULANT;

ADULT; AGED; ARGENTINIAN; ARTICLE; CONTROLLED STUDY; CYP2C9 GENE; DRUG RESPONSE; DRUG SENSITIVITY; ETHNIC GROUP; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MOLECULAR TYPING; POPULATION GENETICS; PRESCRIPTION; PREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE;

ADULT; AGED; ANTICOAGULANTS; ARGENTINA; ARYL HYDROCARBON HYDROXYLASES; COUMARINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; VITAMIN K 1; WARFARIN; YOUNG ADULT;

EID: 84930475711     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2012.January.9.8     Document Type: Article

References (10)

1. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, et al. (2005). A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105: 645-649.
2. Epstein RS, Moyer TP, Aubert RE, O'Kane DJ, et al. (2010). Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55: 2804-2812.
3. Hylek EM, Chang YC, Skates SJ, Hughes RA, et al. (2000). Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch. Intern. Med. 160: 1612-1617.
4. Kamali F and Pirmohamed M (2006). The future prospects of pharmacogenetics in oral anticoagulation therapy. Br. J. Clin. Pharmacol. 61: 746-751.
5. Ku Chee Sehg, Gan Gin Gin, J Vijaya Sangkar and Maude Elvira Phipps (2003). Frequency of cytochrome P450 2C9 (CYP2C9) alleles in three ethnic groups in malaysia. Asian Pac. J. Mol. Biol. 11: 83-91.
6. Martin JH (2009). Pharmacogenetics of warfarin- is testing clinically indicated? Australian Prescriber 32: 76-80.
7. Schwarz UI, Ritchie MD, Bradford Y, Li C, et al. (2008). Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358: 999-1008.
8. Taube J, Halsall D and Baglin T (2000). Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96: 1816-1819.
9. Wen MS, Lee M, Chen JJ, Chuang HP, et al. (2008). Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin. Pharmacol. Ther. 84: 83-89.
10. Yuan HY, Chen JJ, Lee MT, Wung JC, et al. (2005). A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14: 1745-1751.